| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |